Iron-induced fibrin in cardiovascular disease

Current Neurovascular Research

Volumn 10, Issue 3, 2013, Pages 269-274

  Lipinski, Boguslaw ^a   Pretorius, Etheresia ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Cardiovascular disease; Fibrinogen; Free radicals; Inflammation; Iron; Parafibrin; Thrombosis

Indexed keywords

AMPHOPHILE; FIBRIN; FIBRINOGEN; FREE RADICAL; HIGH DENSITY LIPOPROTEIN; HUMAN ALBUMIN; HYDROXYL RADICAL; IRON; LOW DENSITY LIPOPROTEIN; THROMBIN;

ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CATALYSIS; CHRONIC INFLAMMATION; DISSOLUTION; ERYTHROCYTE; FIBRIN CLOT; HUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCANNING ELECTRON MICROSCOPY; STROKE PATIENT;

EID: 84880311179     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/15672026113109990016     Document Type: Article

References (65)

1. Chan MY, Andreotti F, Becker RC. Hypercoagulable states in cardiovascular disease. Circulation. 2008;118(22):2286-97. Epub 2008/11/26.
2. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258(9):1183-6. Epub 1987/09/04.
3. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1995;15(9):1263-8. Epub 1995/09/01.
4. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310-20. Epub 2012/10/05.
5. Astrup T. The biological significance of fibrinolysis. Lancet. 1956;271(6942):565-8. Epub 1956/09/15.
6. Liu S, Marder VJ, Levy DE, Wang SJ, Yang F, Paganini-Hill A, et al. Ancrod and fibrin formation: perspectives on mechanisms of action. Stroke. 2011;42(11):3277-80. Epub 2011/08/27.
7. Lipinski B, Nowak A, Gurewich V. The organ distribution of 125Ifibrin in the generalized Shwartzman reaction and its relation to leucocytes. Br J Haematol. 1974;28(2):221-31. Epub 1974/10/01.
8. Rokitansky K. A Manual of Pathological Anatomy 1852;Vol.IV. London: Sydenham Society.
9. Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol. 1946;58:207-12. Epub 1946/04/01.
10. Kadish JL. Fibrin and atherogenesis-a hypothesis. Atherosclerosis. 1979;33(4):409-13. Epub 1979/08/01.
11. Bini A, Kudryk BJ. Fibrinogen and fibrin in the arterial wall. Thromb Res. 1994;75(3):337-41. Epub 1994/08/01.
12. Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J. 1995;16 Suppl A:11-4; discussion 4-5. Epub 1995/03/01.
13. Ogata J, Yutani C, Kaneko T, Kuriyama Y, Sawada T. Rupture of atheromatous plaque as a cause of thrombotic occlusion of the internal carotid artery. Stroke. 1987;18(6):1175-6. Epub 1987/11/01.
14. Bennett PC, Silverman SH, Gill PS, Lip GY. Peripheral arterial disease and Virchow's triad. Thromb Haemost. 2009;101(6):1032-40. Epub 2009/06/06.
15. Lipinski B, Lewicki Z, Zajdel M, Miks B, Hagel E. Saline extractable acid mucopolysaccharides of human aorta in relation to age, sex and atherosclerosis. Mater Med Pol. 1972;4(1):19-22. Epub 1972/01/01.
16. Undas A, Szuldrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis. 2008;196(2):551-7. Epub 2007/07/21.
17. Lipinski B. Modification of fibrin structure as a possible cause of thrombolytic resistance. J Thromb Thrombolysis. 2010;29(3):296-8. Epub 2009/06/25.
18. Ahluwalia N, Genoux A, Ferrieres J, Perret B, Carayol M, Drouet L, et al. Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. J Nutr. 2010;140(4):812-6. Epub 2010/02/26.
19. Brewer GJ. Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Exp Biol Med (Maywood). 2007;232(2):323-35. Epub 2007/01/30.
20. Depalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. J Vasc Surg. 2010;51(6):1498-503. Epub 2010/03/23.
21. Hahalis G, Kalogeropoulos A, Terzis G, Tselepis AD, Kourakli A, Mylona P, et al. Premature atherosclerosis in non-transfusiondependent beta-thalassemia intermedia. Cardiology. 2011;118(3):159-63. Epub 2011/06/08.
22. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation. 1997;96(10):3300-7. Epub 1997/12/13.
23. Merono T, Rosso LG, Sorroche P, Boero L, Arbelbide J, Brites F. High risk of cardiovascular disease in iron overload patients. Eur J Clin Invest. 2011;41(5):479-86. Epub 2010/12/07.
24. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol. 2010;84(11):825-89. Epub 2010/10/23.
25. Franchini M, Targher G, Montagnana M, Lippi G. Iron and thrombosis. Ann Hematol. 2008;87(3):167-73. Epub 2007/12/11.
26. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803-11. Epub 1992/09/01.
27. Tian J, Hu S, Sun Y, Ban X, Yu H, Dong N, et al. A novel model of atherosclerosis in rabbits using injury to arterial walls induced by ferric chloride as evaluated by optical coherence tomography as well as intravascular ultrasound and histology. J Biomed Biotechnol. 2012;2012:121867. Epub 2012/06/06.
28. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108(16):1912-6. Epub 2003/10/22.
29. Steinhubl SR. Why have antioxidants failed in clinical trials? Am J Cardiol. 2008;101(10A):14D-9D. Epub 2008/06/24.
30. Lipinski B. Hydroxyl radical and its scavengers in health and disease. Oxid Med Cell Longev. 2011;2011:809696. Epub 2011/09/10.
31. Lipinski B, Pretorius E. Novel pathway of ironinduced blood coagulation: implications for diabetes mellitus and its complications. Pol Arch Med Wewn. 2012;122(3):115-22. Epub 2012/03/31.
32. Das D, Luo X, Singh A, Gu Y, Ghosh S, Mukhopadhyay CK, et al. Paradoxical role of prion protein aggregates in redox-iron induced toxicity. PLoS ONE. 2010;5(7):e11420. Epub 2010/07/14.
33. Kwan AH, Winefield RD, Sunde M, Matthews JM, Haverkamp RG, Templeton MD, et al. Structural basis for rodlet assembly in fungal hydrophobins. Proc Natl Acad Sci U S A. 2006;103(10):3621-6. Epub 2006/03/16.
34. Kleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, Wielinga PY, et al. Anti-inflammatory, anti-proliferative and antiatherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis. 2011;218(1):44-52. Epub 2011/05/24.
35. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045-51. Epub 2012/08/17.
36. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-26. Epub 1999/01/14.
37. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-95. Epub 2005/04/22.
38. Hu FB. The iron-heart hypothesis: search for the ironclad evidence. JAMA. 2007;297(6):639-41. Epub 2007/02/15.
39. Menke A, Fernandez-Real JM, Muntner P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. BMC Cardiovasc Disord. 2009;9:34. Epub 2009/08/05.
40. Lele S, Shah S, McCullough PA, Rajapurkar M. Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes. EuroIntervention. 2009;5(3):336-42. Epub 2009/09/09.
41. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF, Jr., et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103(23):2799-804. Epub 2001/06/13.
42. Ferrara DE, Taylor WR. Iron chelation and vascular function: in search of the mechanisms. Arterioscler Thromb Vasc Biol. 2005;25(11):2235-7. Epub 2005/11/01.
43. Kwiatkowski JL. Oral iron chelators. Hematol Oncol Clin North Am. 2010;24(1):229-48. Epub 2010/02/02.
44. Matthews AJ, Vercellotti GM, Menchaca HJ, Bloch PH, Michalek VN, Marker PH, et al. Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1). J Surg Res. 1997;73(1):35-40. Epub 1998/02/14.
45. Zhang WJ, Wei H, Frei B. The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice. Exp Biol Med (Maywood). 2010;235(5):633-41. Epub 2010/05/14.
46. Yuan XM, Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann Med. 2003;35(8):578-91. Epub 2004/01/08.
47. Mehta SR. Aspirin for prevention and treatment of cardiovascular disease. Ann Intern Med. 2009;150(6):414-6. Epub 2009/03/19.
48. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J. 2011;162(5):949-57 e1. Epub 2011/11/19.
49. Nadtochiy SM, Redman EK. Mediterranean diet and cardioprotection: the role of nitrite, polyunsaturated fatty acids, and polyphenols. Nutrition. 2011;27(7-8):733-44. Epub 2011/04/02.
50. Kahle K, Huemmer W, Kempf M, Scheppach W, Erk T, Richling E. Polyphenols are intensively metabolized in the human gastrointestinal tract after apple juice consumption. J Agric Food Chem. 2007;55(26):10605-14. Epub 2007/12/01.
51. Zabczyk M, Hondo L, Krzek M, Undas A. High-density cholesterol and apolipoprotein AI as modifiers of plasma fibrin clot properties in apparently healthy individuals. Blood Coagul Fibrinolysis. 2012. Epub 2012/10/06.
52. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Albumin level and stroke. Potential association between lower albumin level and cardioembolic aetiology. Int J Neurosci. 2011;121(1):25-32. Epub 2010/10/20.
53. Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost. 2010;104(1):100-4. Epub 2010/04/15.
54. Hostmark AT, Tomten SE. Serum albumin and self-reported prevalence of stroke: a population-based, cross-sectional study. Eur J Cardiovasc Prev Rehabil. 2006;13(1):87-90. Epub 2006/02/02.
55. Kim KJ, Yang WS, Kim SB, Lee SK, Park JS. Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin. Perit Dial Int. 1997;17(2):157-61. Epub 1997/03/01.
56. Andresdottir MB, Sigfusson N, Sigvaldason H, Gudnason V. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. Am J Epidemiol. 2003;158(9):844-51. Epub 2003/10/31.
57. Erikssen G, Liestol K, Bjornholt JV, Stormorken H, Thaulow E, Erikssen J. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J. 2000;21(19):1614-20. Epub 2000/09/16.
58. Nagy E, Eaton JW, Jeney V, Soares MP, Varga Z, Galajda Z, et al. Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler Thromb Vasc Biol. 2010;30(7):1347-53. Epub 2010/04/10.
59. Natali A, L'Abbate A, Ferrannini E. Erythrocyte sedimentation rate, coronary atherosclerosis, and cardiac mortality. Eur Heart J. 2003;24(7):639-48. Epub 2003/03/27.
60. Lipinski B, Pretorius E, Oberholzer HM, van der Spuy WJ. Interaction of fibrin with red blood cells: the role of iron. Ultrastruct Pathol. 2012;36(2):79-84. Epub 2012/04/05.
61. Pretorius E, Lipinski B. Iron alters red blood cell morphology. Blood. 2013;121(1):9.
62. Arbel Y, Banai S, Benhorin J, Finkelstein A, Herz I, Halkin A, et al. Erythrocyte aggregation as a cause of slow flow in patients of acute coronary syndromes. Int J Cardiol. 2012;154(3):322-7. Epub 2011/07/26.
63. Cairncross D, Collins GM, Kostalas G, Ludbrook J. Blood viscosity and erythrocyte sedimentation rate in patients with thrombotic arterial disorders. Med J Aust. 1969;1(26):1348-52. Epub 1969/06/28.
64. Zacharski LR, Kyle RA. Significance of extreme elevation of erythrocyte sedimentation rate. JAMA. 1967;202(4):264-6. Epub 1967/10/23.
65. Lipinski B, Worowski K, Mysliwiec M, Farbiszewski R. Erythrocyte sedimentation and soluble fibrin monomer complexes. Thromb Diath Haemorrh. 1969;21(2):196-202. Epub 1969/04/30.